Dean L. Schorno

Dean L. Schorno is a declared insider at 2 companies (finance chief); the most frequent names are Genomic Health Inc and Rigel Pharmaceuticals Inc. In total, 87 filings cover trades dated from 13 January 2011 to 2 September 2026.

Market trades split into 2 purchases (€95k) and 36 sales (€1.6M). Taken together, the sales exceed the purchases by €1.5M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 20 share grants and 29 option exercises.

The newest entry dates from 3 September 2026: an option exercise of €42k, in Rigel Pharmaceuticals Inc. The last insider purchase was made public on 23 May 2019, 2,711 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.